基于生理的药代动力学模型预测多拉韦林和雷特格韦在孕妇及胎儿体内的药代动力学。
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.
机构信息
Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA, USA.
出版信息
Clin Pharmacokinet. 2020 Nov;59(11):1433-1450. doi: 10.1007/s40262-020-00897-9.
Abstract
Predicting drug pharmacokinetics in pregnant women including placental drug transfer remains challenging. This study aimed to develop and evaluate maternal-fetal physiologically based pharmacokinetic models for two antiretroviral drugs, dolutegravir and raltegravir.
摘要
预测包括胎盘药物转运在内的孕妇的药物药代动力学仍然具有挑战性。本研究旨在为两种抗逆转录病毒药物，多替拉韦和拉替拉韦，开发和评估母体-胎儿生理药代动力学模型。
相似文献
1
Prediction of Maternal and Fetal Pharmacokinetics of Dolutegravir and Raltegravir Using Physiologically Based Pharmacokinetic Modeling.基于生理的药代动力学模型预测多拉韦林和雷特格韦在孕妇及胎儿体内的药代动力学。
Clin Pharmacokinet. 2020 Nov;59(11):1433-1450. doi: 10.1007/s40262-020-00897-9.
2
Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure.替诺福韦酯和拉替拉韦在预防艾滋病母婴传播中的应用
Pediatr Infect Dis J. 2022 Feb 1;41(2):131-132. doi: 10.1097/INF.0000000000003364.
3
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.在老年 HIV 感染者中，增效后的达芦那韦、度鲁特韦和拉米夫定的药代动力学特征。
AIDS. 2020 Jan 1;34(1):103-108. doi: 10.1097/QAD.0000000000002372.
4
Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling.整合胎盘体外灌流数据和基于生理的药代动力学模型评估母体和胎儿多替拉韦暴露情况。
Clin Pharmacol Ther. 2020 Jun;107(6):1352-1361. doi: 10.1002/cpt.1748. Epub 2020 Jan 24.
5
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.HIV 整合酶抑制剂在妊娠期的药代动力学：机制、临床意义和知识空白。
Clin Pharmacokinet. 2019 Mar;58(3):309-323. doi: 10.1007/s40262-018-0684-z.
6
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravir.评估 HCV 直接作用抗病毒药物 elbasvir/grazoprevir 与 HIV 整合酶抑制剂raltegravir 和 dolutegravir 之间的药物相互作用潜力。
J Antimicrob Chemother. 2019 Mar 1;74(3):710-717. doi: 10.1093/jac/dky465.
7
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors.HIV-1整合酶链转移抑制剂的比较临床药代动力学和药效学
Clin Pharmacokinet. 2017 Jan;56(1):25-40. doi: 10.1007/s40262-016-0424-1.
8
Comparative Clinical Pharmacokinetics and Pharmacodynamics of HIV-1 Integrase Strand Transfer Inhibitors: An Updated Review.HIV-1 整合酶链转移抑制剂的比较临床药代动力学和药效学：更新综述。
Clin Pharmacokinet. 2020 Sep;59(9):1085-1107. doi: 10.1007/s40262-020-00898-8.
9
The promise of paediatric dolutegravir.儿科多替拉韦的前景。
J Int AIDS Soc. 2021 Jan;24(1):e25660. doi: 10.1002/jia2.25660.
10
Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?在妊娠期间，多拉韦林和整合酶抑制剂是否存在安全信号？
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):481-486. doi: 10.1097/QAI.0000000000002065.
引用本文的文献
1
Safety and Efficacy of Antiviral Drugs and Vaccines in Pregnant Women: Insights from Physiologically Based Pharmacokinetic Modeling and Integration of Viral Infection Dynamics.抗病毒药物和疫苗在孕妇中的安全性与有效性：基于生理的药代动力学建模及病毒感染动力学整合的见解
Vaccines (Basel). 2024 Jul 16;12(7):782. doi: 10.3390/vaccines12070782.
2
Challenges, risks, and opportunities of antiretroviral drugs in women of reproductive potential.具有生殖潜能的女性使用抗逆转录病毒药物面临的挑战、风险和机遇。
Expert Rev Anti Infect Ther. 2024 Apr;22(4):153-167. doi: 10.1080/14787210.2024.2334054. Epub 2024 Mar 27.
3
Physiologically-based pharmacokinetic modelling of long-acting injectable cabotegravir and rilpivirine in pregnancy.长效注射用卡博特韦和利匹韦林在妊娠期的基于生理的药代动力学建模
Br J Clin Pharmacol. 2025 Apr;91(4):989-1002. doi: 10.1111/bcp.16006. Epub 2024 Feb 10.
4
Application of Physiologically Based Pharmacokinetic Modeling to Predict Maternal Pharmacokinetics and Fetal Exposure to Oxcarbazepine.基于生理的药代动力学模型在预测母体奥卡西平药代动力学及胎儿暴露情况中的应用。
Pharmaceutics. 2022 Nov 3;14(11):2367. doi: 10.3390/pharmaceutics14112367.
5
Maternal-Fetal Pharmacology of Drugs: A Review of Current Status of the Application of Physiologically Based Pharmacokinetic Models.药物的母胎药理学：基于生理药代动力学模型应用现状的综述
Front Pediatr. 2021 Nov 3;9:733823. doi: 10.3389/fped.2021.733823. eCollection 2021.
6
Mechanistic Modeling of Placental Drug Transfer in Humans: How Do Differences in Maternal/Fetal Fraction of Unbound Drug and Placental Influx/Efflux Transfer Rates Affect Fetal Pharmacokinetics?人类胎盘药物转运的机制模型：母体/胎儿未结合药物分数及胎盘流入/流出转运速率的差异如何影响胎儿药代动力学？
Front Pediatr. 2021 Oct 18;9:723006. doi: 10.3389/fped.2021.723006. eCollection 2021.
7
Characterization of Plasma Protein Alterations in Pregnant and Postpartum Individuals Living With HIV to Support Physiologically-Based Pharmacokinetic Model Development.对感染艾滋病毒的孕妇和产后个体血浆蛋白变化的特征分析，以支持基于生理的药代动力学模型开发。
Front Pediatr. 2021 Oct 13;9:721059. doi: 10.3389/fped.2021.721059. eCollection 2021.
8
Mechanistic Coupling of a Novel Cotyledon Perfusion Model and a Physiologically Based Pharmacokinetic Model to Predict Fetal Acetaminophen Pharmacokinetics at Delivery.一种新型子叶灌注模型与基于生理的药代动力学模型的机制耦合，以预测分娩时胎儿对乙酰氨基酚的药代动力学。
Front Pediatr. 2021 Sep 23;9:733520. doi: 10.3389/fped.2021.733520. eCollection 2021.
9
Mechanistic Modeling of Maternal Lymphoid and Fetal Plasma Antiretroviral Exposure During the Third Trimester.孕晚期母体淋巴细胞和胎儿血浆中抗逆转录病毒药物暴露的机制建模
Front Pediatr. 2021 Sep 20;9:734122. doi: 10.3389/fped.2021.734122. eCollection 2021.
10
Regulatory Considerations for the Mother, Fetus and Neonate in Fetal Pharmacology Modeling.胎儿药理学建模中母亲、胎儿和新生儿的监管考量
Front Pediatr. 2021 Jul 26;9:698611. doi: 10.3389/fped.2021.698611. eCollection 2021.
本文引用的文献
1
Impact of gastrointestinal physiology on drug absorption in special populations--An UNGAP review.特殊人群中胃肠道生理学对药物吸收的影响——UNGAP 综述。
Eur J Pharm Sci. 2020 Apr 30;147:105280. doi: 10.1016/j.ejps.2020.105280. Epub 2020 Feb 25.
2
The Effect of Pregnancy on the Pharmacokinetics of Total and Unbound Dolutegravir and Its Main Metabolite in Women Living With Human Immunodeficiency Virus.妊娠对人类免疫缺陷病毒感染者体内多拉韦林及其主要代谢物的总浓度和游离浓度的药代动力学的影响。
Clin Infect Dis. 2021 Jan 23;72(1):121-127. doi: 10.1093/cid/ciaa006.
3
Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).替诺福韦酯/拉米夫定/多替拉韦在 HIV 感染孕妇及其新生儿中的安全性和药代动力学：一项随机试验（DolPHIN-1 研究）。
PLoS Med. 2019 Sep 20;16(9):e1002895. doi: 10.1371/journal.pmed.1002895. eCollection 2019 Sep.
4
Drug Transporters Expressed in the Human Placenta and Models for Studying Maternal-Fetal Drug Transfer.人胎盘表达的药物转运体及其用于研究母胎药物转运的模型。
J Clin Pharmacol. 2019 Sep;59 Suppl 1(Suppl 1):S70-S81. doi: 10.1002/jcph.1491.
5
Physiologically Based Pharmacokinetic Models to Predict Maternal Pharmacokinetics and Fetal Exposure to Emtricitabine and Acyclovir.基于生理学的药代动力学模型预测恩曲他滨和阿昔洛韦在母体中的药代动力学和胎儿暴露情况。
J Clin Pharmacol. 2020 Feb;60(2):240-255. doi: 10.1002/jcph.1515. Epub 2019 Sep 6.
6
Physiologically Based Pharmacokinetic Modeling to Characterize Acetaminophen Pharmacokinetics and N-Acetyl-p-Benzoquinone Imine (NAPQI) Formation in Non-Pregnant and Pregnant Women.基于生理学的药代动力学模型来描述非妊娠和妊娠妇女对乙酰氨基酚的药代动力学和 N-乙酰对苯醌亚胺（NAPQI）的形成。
Clin Pharmacokinet. 2020 Jan;59(1):97-110. doi: 10.1007/s40262-019-00799-5.
7
Clinical Extrapolation of the Effects of Dolutegravir and Other HIV Integrase Inhibitors on Folate Transport Pathways.多替拉韦及其他 HIV 整合酶抑制剂对叶酸转运途径影响的临床外推。
Drug Metab Dispos. 2019 Aug;47(8):890-898. doi: 10.1124/dmd.119.087635. Epub 2019 Jun 5.
8
Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin.多替拉韦 100 毫克每日一次与利福平合用的药代动力学。
Int J Antimicrob Agents. 2019 Aug;54(2):202-206. doi: 10.1016/j.ijantimicag.2019.04.009. Epub 2019 Apr 16.
9
Reconsidering the Number of Women With HIV Infection Who Give Birth Annually in the United States.重新考虑美国每年艾滋病毒感染的女性生育人数。
Public Health Rep. 2018 Nov;133(6):637-643. doi: 10.1177/0033354918800466. Epub 2018 Sep 28.
10
Physiologically Based Pharmacokinetic Modeling in Pregnancy: A Systematic Review of Published Models.妊娠的生理药代动力学模型：已发表模型的系统评价。
Clin Pharmacol Ther. 2018 Dec;104(6):1110-1124. doi: 10.1002/cpt.1084. Epub 2018 May 6.
Zotero 插件